Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Board of Directors

Masoud Tavazoie, M.D., Ph.D.

Masoud, M.D., Ph.D., is co-founder, Board Director, and the Chief Executive Officer of Rgenix.

Eric Rowinsky, M.D.

Eric K. Rowinsky, M.D., is the Executive Chairman of Rgenix and Chair of its Clinical Advisory Board.

Nancy Chang, Ph.D.

Nancy T. Chang is an investor in and Director at Rgenix. Dr. Chang is a renowned biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation, and diseases affecting the human immune system.

Saeed Tavazoie, Ph.D.

Saeed is a Professor in the Department of Biochemistry and Molecular Biophysics at Columbia University.

Antoine Papiernik

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997.

Nilesh Kumar

Nilesh joined Novo Ventures (U.S.) Inc. in Boston in 2015. Prior to joining Novo, Nilesh was Senior Director at MS Ventures where he invested in early stage life science companies.

Peter Van Vlasselaer, Ph.D.

Peter Van Vlasselaer, PhD has over 20 years of experience in the biotech industry. He was most recently the Founder, President and Chief Executive Officer of ARMO Biosciences.

Jue Pu

Jue leads the cancer biomarker and liquid biopsy research and development at Lepu Medical.